Gabriela Hobbs: Emerging Myelofibrosis Therapies at EHA 2026
Gabriela Hobbs, Leukemia Clinical Director at Massachusetts General Hospital, Associate Professor at Harvard Medical School, shared Priya Sriskandarajah’s post on LinkedIn:
“Thankful for the opportunity to discuss emerging therapies in Myelofibrosis at this year’s EHA in lovely Sweden with Stefan Schleding, Gonzalo Carreño and Steffen Koschmieder.”
Priya Sriskandarajah, Consultant Haematologist at Guy’s and St Thomas’ NHS Foundation Trust, shared a post on LinkedIn:
“Next session covering management of cytopenic myelofibrosis – a very challenging cohort but some exciting new therapies coming especially combination options.
Excellent presentations by Stefan Scheding, Gonzalo Carreno and Gabriela Hobbs with chair Steffen Koschmieder.”
Stay updated with Hemostasis Today.
-
Sep 19, 2026, 18:03Manisha Madkaikar: Clinical, Hematological, and Molecular Features of Sickle β-Thalassemia
-
Sep 19, 2026, 17:24Jan Shawqi Goran: Understanding Beta Thalassemia Before Marriage Testing
-
Sep 19, 2026, 14:17Abdul Mannan: What Exactly Is a Platelet?
-
Sep 19, 2026, 13:39Keisuke Goda: Decoding Platelet Phenotypes in COVID-19 With Optofluidic Imaging
-
Sep 19, 2026, 13:30Targeted Thrombolysis Beyond tPA
-
Sep 19, 2026, 13:21Paul Armstrong: From Summer Studentship to Young Researcher
-
Sep 19, 2026, 13:06Rabiya Masood: Breaking the Cycle of Thalassemia Through Screening
-
Sep 19, 2026, 10:52Consuela A. Albright: The Critical Role of Black Blood Donors in Sickle Cell Treatment
-
Sep 19, 2026, 10:47Amber Yates: Inside Agios’ Partnership with the Sickle Cell Community